Myeloma bone disease
Antisense inhibition of macrophage inflammatory protein 1 α blocks bone destruction in a model of myeloma bone disease
... Myeloma bone disease is characterized by lytic bone lesions with little or no reactive new bone ...multiple myeloma (MM) patients pres- ent with bone pain, and over 70% of ...
10
A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease
... of myeloma bone ...increase bone mass. The increase in bone mass appears to parallel the increase in osteoblast ...vent bone loss as well as increase bone formation to ...
17
NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease
... multiple myeloma vary in terms of consistency of onset, degree of tumour burden and degree of myeloma bone ...of myeloma in NOD/SCID-GAMMA mice to specifically study the effects of therapeutic ...
14
Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis
... and bone marrow microenvironment has important impacts on the initiation and progression of myeloma bone disease [6, ...of bone disease and estimates patient progression and ...
12
Tumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease
... Although both soluble factors and cell-to-cell contact between MM cells and BM-MSCs or OB progenitors have been shown to be involved in the suppression of OB differentiation in MM, the mechanisms underlying these ...
14
Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease
... histological bone sec- tions stained for TRAP (Figure 7C) showed a significantly higher number of OCs (Figure 7D), with increased surface area (Figure 7E) in mice treated with GM3 plus PBS, an effect that was ...
15
LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease
... LIGHT is a member of TNFSF (TNFSF14) expressed on cells with an immunological role such as activated T-cells, monocytes, granulocytes, spleen cells, and immature dendritic cells [15, 16]. As membrane- anchored or ...
18
Activin a promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
... Mouse Model. All animal studies were conducted according to protocols approved by the Institutional Animal Care and Use Committee. The SCID-hu model was generated as previously described (20). Four weeks after INA6 ...
7
Multiple Myeloma associated Bone Disease
... lytic bone disease is a hallmark of multiple myeloma, being present in about 80% of patients with newly diagnosed MM, and in more during the disease ...The myeloma associated ...
24
Prognosis in monoclonal proteinaemia
... of bone marrow examination and skeletal x-rays, and therapy were documented ...of disease, the serum was not taken at diagnosis or an insufficient amount was left for the syndecan-1 ...a bone marrow ...
144
Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma
... trabecular bone in 5T2MM bearing mice compared to non-tumour bearing, naı¨ve mice (Figure 4A and 4B), although, bone loss was also associated with significant infiltration of 5T2MM tumour ...increased ...
10
Bisphosphonate related osteonecrosis of the jaws: A report on 30 cases
... [27] Khosla, S., Burr, D., Cauley, J., Dempster, D.W., Ebeling, P.R., Felsenberg, D., Gagel, R.F., Gilsanz, V., Guise, T., Koka, S., McCauley, L.K., McGowan, J., McKee, M.D., Mohla, S., Pendrys, D.G., Raisz, L.G., ...
8
The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma
... human myeloma cells via c-mpl- independent pathways, either alone or in combination with other hematopoietic growth factors such as granulo- cyte colony-stimulating factor (G-CSF) and erythropoietin (EPO), which ...
11
Original Article Anti-myeloma properties and mechanism of polymethyl methacrylate bone cement and allograft bone in vitro
... of disease progression [4, ...plus bone defect fillers, and plate internal fixation. PMMA bone cement and allograft bone are widely used in surgery because of their good biocompatibility ...
6
Multiple Myeloma Update
... to bone marrow infiltration of neoplastic plasma cells. When myeloma crowds the bone marrow, there are less hematopoietic stem cells, and therefore less platelets, erythrocytes, and ...to bone ...
6
Molecular pathogenesis of multiple myeloma and its premalignant precursor
... Multiple myeloma (MM) is an age-dependent monoclonal tumor of BM plasma cells ...lytic bone lesions, anemia, immunodeficiency, and decreased renal func- tion ...incurable disease, but the median ...
9
Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
... In our institution, we perform a comprehensive SMM workup (Table 2) including both PET-CT and WB-MRI. We also plan to extend it by adding immunprofiling and next generation flow cytometry in the near future. Currently, ...
11
Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease
... 1. Bone lesions were in a rank order: back (n = 23/25), ribs (n = 7/25), skull (n = 5/25), neck (n = 4/25), long bones (n = 3/25), pelvis (n = 3/25), others (n = ...
10
Bone Marrow Morphology in Multiple Myeloma.
... Multiple myeloma is a clonal plasma cell disorder that varies widely in its clinical course ranging from relatively indolent forms to frankly aggressive neoplasia [1] ...chains. Bone marrow examination ...
87
FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS
... on IMWG criteria (2), staging of patients was done using Durie-salmon criteria (7). treatment responses were eval- uated only in patients who had a follow-up longer than 6 weeks. Response to therapy, progression or ...
5